| Size | Price | Stock | Qty |
|---|---|---|---|
| 10mg |
|
||
| 25mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| 250mg |
|
||
| 500mg |
|
||
| 1g |
|
||
| Other Sizes |
|
Purity: =98.35%
Anisomycin (Wuningmeisu C, NSC76712, AI3-50846, Flagecidin), a naturally occurring bacterial antibiotic isolated from Streptomyces griseolus, is a novel, potent, and specific activator (agonist) of JNK (c-Jun N-terminal Kinase) with potential antineoplastic activity. It is also a potent and reversible inhibitor of protein synthesis in eukaryotic organisms. It does this by binding to and inhibiting the activity of the 60S ribosomal subunit's peptidyl transferase.
| Targets |
JNK; DNA synthesis
|
|---|---|
| ln Vitro |
Anisomycin (3 μM) decreases MDA16 and MDA-MB-468 cell protein synthesis and MDA-MB-468 cell colony formation. In MDA-MB-468 cultures, anisomycin increases the number of apoptotic cells, but not in MDA16 cultures. In MDA-MB-468 cells, anisomycin activates JNK phosphorylation. [2] Anisomycin inhibits cell growth in U251 and U87 cells in a concentration- and time-dependent manner with an IC50 (48 h) value of 0.233 and 0.192 μmol/L, respectively. In U251 and U87 cells, respectively, anisomycin (4 μM) induces 21.5% and 25.3% of apoptosis proportion and activates p38 MAPK and JNK while inactivating ERK1/2. In U251 and U87 cells, anisomycin (4 μM) decreases the level of PP2A/C subunit in a time-dependent manner. [3] The proliferation of EAC cells is inhibited by anisomycin in a concentration-dependent manner. [4]
|
| ln Vivo |
Anisomycin (5 mg/kg) administered intraperitoneally significantly slows the growth of Ehrlich ascites carcinoma (EAC), resulting in a 60% mouse survival rate 90 days after EAC inoculation.[4]
|
| Enzyme Assay |
In 6-well plates, 500,000 cells are seeded per well and left to incubate overnight. Following that, test compounds or DMSO as a vehicle control are incubated with cells for 1 hour at a final concentration of 1% v/v. To label developing polypeptide chains, puromycin (final concentration: 18 μM) is added, and cells are then incubated for an additional 10 min. By incubating cells without puromycin, background labeling is ascertained. Following a HBSS wash, scraping cell harvest, and 5-minute, 300-g centrifugation, cells are isolated. 0.5 mL of 50 mM DTT containing phosphatase inhibitors is used to resuspend the cells, and they are then incubated at 95°C for 10 min. Samples are then immediately frozen in liquid nitrogen and kept at -20°C until blotted. Samples (20–30 g of protein per sample) are blotted onto a PVDF membrane. Anti-phospho-Thr183/Tyr185-JNK antibody is applied to the membrane after it has been blocked and incubated at 4 °C overnight. An infrared scanner is used to detect secondary antibodies that are used to label the primary antibody. Anti-phospho-JNK antibody fluorescence signal strength is background adjusted and loaded-normalized.
|
| Cell Assay |
EAC cells are plated in 96-well plates at a density of 10,000 cells/well and 200 µL of medium for the assay. Anisomycin is applied to the cells in a variety of concentrations for 48 hours. As a positive control, adriamycin (500 ng/mL) is used. MTT is added to every well at a concentration of 0.5 mg/mL. The formazan product of the MTT reduction is dissolved in DMSO 4 hours later, and an absorbance measurement at 570 nm is made using a Model 680 microplate reader.
|
| Animal Protocol |
Balb/c mice of both sexes (4-5 weeks old)
84, 99, 116, 136 or 160 mg/kg; 0.2 mL per mouse Intravenously injected through mouse tail vein |
| References |
| Molecular Formula |
C14H19NO4
|
|
|---|---|---|
| Molecular Weight |
265.3
|
|
| Exact Mass |
265.13
|
|
| Elemental Analysis |
C, 63.38; H, 7.22; N, 5.28; O, 24.12
|
|
| CAS # |
22862-76-6
|
|
| Related CAS # |
|
|
| Appearance |
Solid powder
|
|
| SMILES |
CC(=O)O[C@@H]1[C@H](CN[C@@H]1CC2=CC=C(C=C2)OC)O
|
|
| InChi Key |
YKJYKKNCCRKFSL-RDBSUJKOSA-N
|
|
| InChi Code |
InChI=1S/C14H19NO4/c1-9(16)19-14-12(15-8-13(14)17)7-10-3-5-11(18-2)6-4-10/h3-6,12-15,17H,7-8H2,1-2H3/t12-,13+,14+/m1/s1
|
|
| Chemical Name |
[(2R,3S,4S)-4-hydroxy-2-[(4-methoxyphenyl)methyl]pyrrolidin-3-yl] acetate
|
|
| Synonyms |
Wuningmeisu C; NSC 76712; AI3 50846; NSC-76712; AI-350846; NSC76712; AI350846; Flagecidin
|
|
| HS Tariff Code |
2934.99.9001
|
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
|
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
|
|||
|---|---|---|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (9.42 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (9.42 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (9.42 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. Solubility in Formulation 4: 2% DMSO+corn oil: 5mg/mL |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.7693 mL | 18.8466 mL | 37.6932 mL | |
| 5 mM | 0.7539 mL | 3.7693 mL | 7.5386 mL | |
| 10 mM | 0.3769 mL | 1.8847 mL | 3.7693 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
|
|
|
|
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
COA
